Literature DB >> 28094601

Recruiting newly referred lung cancer patients to a patient navigator intervention (PACO): lessons learnt from a pilot study.

Trille Kristina Kjær1, Anders Mellemgaard2, Marianne Stensøe Oksen2, Bo Andreassen Rix3, Randi Karlsen1, Christoffer Johansen1,4, Susanne Oksbjerg Dalton1.   

Abstract

OBJECTIVES: The incidence of and survival from lung cancer are associated with socioeconomic position, and disparities have been observed in both curative and palliative treatment for lung cancer. 'Patient navigation' is valuable in addressing health disparity, with timely treatment and transition to care. We conducted a pilot study to test the feasibility of a patient navigator program (PAtient COach) for newly diagnosed lung cancer. We present the trial, the findings from the pilot study and discuss factors that might have affected recruitment rates.
MATERIAL AND METHODS: We invited 24 lung cancer patients referred for chemotherapy to the Oncology Department at Herlev University Hospital, Denmark, to participate in the pilot study. To be eligible, patients had to live alone, have no formal education beyond secondary school, have one or more comorbid conditions, have a performance status of 1 or 2 or be over 65 years of age. The patient navigators targeted four phases of treatment: planning, initiation, compliance and end of treatment.
RESULTS: Six months after the start of the study, we had recruited only six patients, due mainly to inherent patient resistance and because only 50% of eligible patients were invited. Of the 18 patients who did not wish to participate, 13 agreed to fill in a baseline questionnaire. The most frequent reason given for not wanting to participate was a belief that a patient navigator would be of no benefit.
CONCLUSIONS: The pilot study met a number of internal and external obstacles to patients' recruitment. The study provides insight into the barriers to recruitment of socially disadvantaged cancer patients to clinical trials and will inform future trial designs.

Entities:  

Mesh:

Year:  2017        PMID: 28094601     DOI: 10.1080/0284186X.2016.1267871

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

1.  ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes.

Authors:  Amit Joshi; Nikhil Pande; Vanita Noronha; Vijay Patil; Rajiv Kumar; Anuradha Chougule; Vaishakhi Trivedi; Amit Janu; Abhishek Mahajan; Kumar Prabhash
Journal:  Ecancermedicalscience       Date:  2019-01-29

2.  Lung Cancer Pre-Diagnostic Pathways from First Presentation to Specialist Referral.

Authors:  Satya Rashi Khare; Sreenath Arekunnath Madathil; Gerald Batist; Isabelle Vedel
Journal:  Curr Oncol       Date:  2021-01-11       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.